Novartis Shares Rise After Trial Data Supports New Filing for Cancer Drug
By Adria Calatayud
Novartis shares traded higher after the company said data from a late-stage trial in prostate cancer therapy Pluvicto support its plan to file for a label expansion in the second half.
At 1509 GMT on Thursday, shares in Novartis were up 3.1% at CHF88.50, having traded down slightly before the announcement, and were up 4.3% since the start of 2024.
The Swiss pharmaceutical giant confirmed its plans to file in the second half of 2024 for a label expansion of Pluvicto for treatment of patients with advanced prostate cancer before they receive chemotherapy based on a class of drugs known as taxane. Last year, the company delayed the regulatory submission for the label expansion.
Pluvicto is a radiotherapy that combines a cell-targeting compound with a therapeutic radioactive particle. It was Novartis's fastest-growing drug in 2023, with sales more than tripling to $980 million.
Novartis said updated results from a phase 3 trial showed a hazard ratio--a measure often used in cancer studies to compare survival rates in two groups of patients--of less than 1.0.
Pluvicto's safety profile was consistent with previous interim analyses published in 2023 after an additional eight months of data, as were radiographic progression free survival and other secondary efficacy goals, the company said.
Full results from the trial will be presented at an upcoming medical congress, Novartis said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 04, 2024 11:34 ET (15:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software